Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Single-Blind, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Hemolink[Tm] (o-Raffinose Cross-Linked Human Hemoglobin) in Subjects Undergoing Primary Coronary Artery Bypass Grafting Surgery

NCT00038454 is registered in ClinicalTrials.gov with Hemosol as lead sponsor.

NCT NCT00038454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00038454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Single-Blind, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Hemolink[Tm] (o-Raffinose Cross-Linked Human Hemoglobin) in Subjects Undergoing Primary Coronary Artery Bypass Grafting Surgery
Lead sponsor
Hemosol
Phase
Phase 2/3
Overall status
Suspended
Start date
Not reported
Completion date
Not reported
Enrollment
180
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease